Ever since their discovery and isolation of human embryonic stem cells (hESCs) have been touted as the future of regenerative medicine. There is a heavy burden of promise and expectation placed upon them to deliver an unprecedented number of cell-based therapies. Recent advancement in the field of stem cell biology has revolutionized biomedical research and therapy. Off late, the application of stem cells in human medicine is well accepted and became common in chronic and accidental injuries. Since the remarkable discovery of iPSCs, the field has continued to evolve with exciting discoveries furthering our understanding of early development, the process of cellular reprogramming, acquisition and maintenance of pluripotency, determination of cell fate and enhancing our ability to model diseases in vitro. These advances and the possibility of generating patient or disease specific pluripotent stem cells placed the field on a trajectory that may lead to personalized cell therapy in the future.
Module A: Introduction to Stem Cell Biology
Developmental Biology and Human Embryology
Introduction to Stem Cells and Regenerative Medicine
Processes linking stem cells, primary cell function, and structural development
The Discovery of iPSCs and the four factors.
Module B: Recent advances in clinical applications of stem cells Principles of development for stem cell engineering Regenerative biology Inter-tissue communications in regeneration Regenerative medicine & ageing Translation to therapy Engineering solutions to regenerative medicine.
Module C: Policies and Ethics-Debate Legal and Global Perspectives Controversies.
Module D: Hands on Training (Maximum 15 participants, following a selection process).
Interested candidates must login at GIAN-MHRD website (http://www.gian.iitkgp.ac.in/) to fill application.
Please submit your detailed resume along with statement of purpose.
For more details contact: firstname.lastname@example.org or Visit http://www.sls.uohyd.ac.in/stemcells
For mode of payment please visit: http://www.sls.uohyd.ac.in/stemcells.
The above fee includes all instructional materials, computer use for tutorials, 24 hr free internet facility. The participants will be provided with single bedded accommodation on payment basis.
Dr. Mohan Vemuri, is the Director of Research and Development for Cell Biology at Thermo Fisher Scientific. In this capacity, Dr. Vemuri leads R&D activities in stem cell product development in the areas of human iPSCs and adult stem cells. Prior to this role, Dr. Vemuri served on the faculty at Children’s Hospital of Philadelphia where his research efforts focused on developing improved methods for fetal transplantation of engineered hematopoietic stem cells for blood and bone marrow transplantation. Dr. Vemuri previously served on the faculty at Thomas Jefferson Medical School as well as at University of Hyderabad. Dr. Vemuri has authored over 50 publications and has edited or co-edited several stem cell focused books, including Stem Cell Assays, Regulatory Networks in Stem Cells, MSC assays and applications, MSCs and Cell Therapy, Neural Development and Stem Cells and most recently, Pluripotent Stem Cell Assays by Springer Press.
Prof. Polani Seshagiri, PhD, FNASc, FAMS, is a Professor at the Dept. of Molecular Reproduction, Development and Genetics (MRDG), Indian Institute of Science (IISc) Bangalore, India. He completed PhD from Indian Institute of Science and Post-Doctoral training at Dept. of Veterinary Science, Univ. of WI (UW), Madison, USA. Subsequently, he joined as a faculty at Primate Research Centre, UW-Madison, USA. Later, he joined as a faculty of MRDG, IISc, Bangalore. His research interest is studying early mammalian development, with particular reference to blastocyst development and differentiation. Besides, his lab is studying cell-lineage specification and differentiation by using ESC & iPSCs. He has co-authored more than 100 primary articles, reviews and editorials on different aspects of development biology and stem cell biology. He has acted as a scientific consultant for a broad range of constituencies in academia, government (India) regulatory affairs and industry.
Dr. Mahendra Rao, Vice President for Regenerative Medicine at The New York Stem Cell Foundation Research Institute. Dr. Rao, who holds an MD degree and a PhD in developmental neurobiology, is one of the nation’s most prominent stem cell scientists. He has over twenty years of experience in all aspects of the stem cell field including government, academia, and business. Before joining NYSCF, Dr. Rao was the Director of the NIH Center for Regenerative Medicine since its founding in 2010. Prior to joining the NIH, Dr. Rao spent six years as the vice president of Regenerative Medicine at Life Technologies, Inc. (now Thermo Fisher Scientific) after serving as the chief of Neurosciences at the National Institute on Aging and co-founding Q Therapeutics, a neural stem cell company based in Utah. Dr. Rao is tenured at the University of Utah School of Medicine in both Neurobiology and Anatomy and has over twenty submitted and ten issued patents. Dr. Rao, has recently joined inStem to lead the Accelerator program for Discovery in Brain disorders using Stem cells (ADBS) program at the Cluster.
Dr. Gopal Pande, obtained his Ph.D. degree in 1981 from the University of Bombay, India, on cytogenetic studies on acute myeloid leukemia and joined Centre for Cellular and Molecular Biology (CCMB) as a Scientist in 1982. His research interests include the role of integrins in regulation of growth of cell adhesion and motility, differentiation of normal and leukemic hematopoetic cells and the developmental biology of Dictyostelium discoideum with special reference to the role of intracellular calcium and cell cycle. His group has recently initiated work on preparing new substrates for tissue engineering of the osteogenic cells.
Dr. Mahmood Khan, M.Pharm, PhD, FAHA, is an Assistant Professor in the Department of Emergency Medicine and Physiology and Cell Biology at The Ohio State University Wexner Medical Center, Davis Heart and Lung Research Institute, Columbus, OH, USA. Dr. Khan has over a decade of experience in stem cells and myocardial infarction models in rodents. Dr. Khan’s research is focused on utilizing stem cells for treatment of the damaged heart following myocardial infarction using non-embryonic stem cells derived from either mesenchymal stem cells (MSCs) or human inducible pluripotent stem cells (hiPSC) derived cardiomyocytes for the repair and regeneration of the damaged heart. The major focus of his lab is to develop novel therapeutic approaches to enhance the survival and engraftment of stem cells post-transplantation in the ischemic heart, thereby attenuating cardiac remodeling. Currently his lab is focusing on developing and testing novel biodegradable aligned nanofiber cardiac patch and angiogenic scaffolds for cardiac repair.